Specific Signatures of Serum miRNAs as Potential Biomarkers to Discriminate Clinically Similar Neurodegenerative and Vascular-Related Diseases
- PMID: 31691877
- PMCID: PMC11448951
- DOI: 10.1007/s10571-019-00751-y
Specific Signatures of Serum miRNAs as Potential Biomarkers to Discriminate Clinically Similar Neurodegenerative and Vascular-Related Diseases
Abstract
Neurodegenerative diseases (NDs) are age-dependent; among them, Alzheimer's disease (AD) and Parkinson's disease (PD) are the most frequent. Similarly, cerebrovascular damage can induce the development of vascular-related disorders that share common features with AD and PD, respectively, named vascular dementia (VD) and vascular parkinsonism (VP). To date, ND diagnosis is mainly clinical; therefore, since these disorders show similar symptoms, their correct discrimination may be difficult. We detected 23 ND-associated microRNAs (miRNAs) by literature mining and investigated their serum expression in a cohort of 139 patients including AD, PD, VD, and VP patients and healthy controls. TaqMan RT-PCR data showed that miR-23a upregulation was associated with an ongoing neurodegenerative process, similar to miR-22* and miR-29a, while let-7d, miR-15b, miR-24, miR-142-3p, miR-181c, and miR-222 showed an altered expression in Parkinson-like phenotypes, as well as miR-34b, miR-125b, and miR-130b in Alzheimer-like disorders. By computing logistic regression models and ROC curves, we identified signatures of neuro-miRNAs specific for each disease, showing good diagnostic performance. Interestingly, we found that miR-23a, miR-29a, miR-34b, and miR-125b exhibited a different distribution between exosomes and vesicle-free serum, suggesting a heterogeneity of secretion for these miRNAs. Our results suggest that miRNA signatures could discriminate in a non-invasive manner neurodegenerative disorders, thus improving clinical diagnoses.
Keywords: Alzheimer’s disease; Exosomes; Parkinson’s disease; Vascular dementia; Vascular parkinsonism; microRNAs.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures



References
-
- Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 108(12):5003–5008. 10.1073/pnas.1019055108 - PMC - PubMed
-
- Bayer TA (2015) Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders? Eur Neuropsychopharmacol 25(5):713–724. 10.1016/j.euroneuro.2013.03.007 - PubMed
-
- Blennow K, Vanmechelen E, Hampel H (2001) CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease. Mol Neurobiol 24(1–3):87–97. 10.1385/MN:24:1-3:087 - PubMed
-
- Botta-Orfila T, Morato X, Compta Y, Lozano JJ, Falgas N, Valldeoriola F, Pont-Sunyer C, Vilas D, Mengual L, Fernandez M, Molinuevo JL, Antonell A, Marti MJ, Fernandez-Santiago R, Ezquerra M (2014) Identification of blood serum micro-RNAs associated with idiopathic and LRRK2 Parkinson’s disease. J Neurosci Res 92(8):1071–1077. 10.1002/jnr.23377 - PubMed
-
- Burns A, Iliffe S (2009) Alzheimer’s disease. BMJ 338:b158. 10.1136/bmj.b158 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical